Corrigendum to: PROTAC technology for prostate cancer treatment

Corrigendum to: PROTAC technology for prostate cancer treatment

Saved in:

Bibliographic Details
Main Authors:	Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei
Format:	Article
Language:	English
Published:	Compuscript Ltd 2025-07-01
Series:	Acta Materia Medica
Online Access:	https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2025-1005
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PROTAC technology for prostate cancer treatment
by: Zhen Wang, et al.
Published: (2025-01-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-11-01)

Application of PROTACs in target identification and validation
by: Yang Liu, et al.
Published: (2024-02-01)

Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
by: Zhao K, et al.
Published: (2025-06-01)

Advancing Design Strategy of PROTACs for Cancer Therapy
by: Hang Luo, et al.
Published: (2025-07-01)

PROTACs for BRDs proteins in cancer therapy: a review
by: Chao Wang, et al.
Published: (2022-12-01)

PROTAC Technology as a New Tool for Modern Pharmacotherapy
by: Natalia Kubryń, et al.
Published: (2025-05-01)

Computational strategies for PROTAC drug discovery
by: Jia Wu, et al.
Published: (2023-01-01)

PROTAC<sup>®</sup> technology and potential for its application in infection control
by: M. A. Zakharova, et al.
Published: (2024-07-01)

Corrigendum to “Modeling PROTAC degradation activity with machine learning” [Artif. Intell. Life Sci. 6 (2024) 100104]
by: Stefano Ribes, et al.
Published: (2024-12-01)

Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs
by: Chungen Li, et al.
Published: (2024-11-01)

Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues
by: Hany E. Marei, et al.
Published: (2025-06-01)

Corrigendum: Germline mutations in patients with early-onset prostate cancer
by: Tang Tang, et al.
Published: (2024-12-01)

PROTACs improve selectivity for targeted proteins
by: Lihua Liu, et al.
Published: (2025-04-01)

MEGA PROTAC, MEGA DOCK-based PROTAC mediated ternary complex formation pipeline with sequential filtering and rank aggregation
by: Sadettin Y. Ugurlu, et al.
Published: (2025-02-01)

Aging and cancer hallmarks as therapeutic targets
by: Jingchao Wang, et al.
Published: (2023-06-01)

Molecular features defining the efficiency of bioPROTACs
by: Dorothea Winkelvoß, et al.
Published: (2025-06-01)

Modeling PROTAC degradation activity with machine learning
by: Stefano Ribes, et al.
Published: (2024-12-01)

Corrigendum to “PRMT1 methylates METTL14 to modulate its oncogenic function” [Neoplasia 42 (2023) 100912]
by: Jingchao Wang, et al.
Published: (2025-07-01)

Linker-free PROTACs efficiently induce the degradation of oncoproteins
by: Jianchao Zhang, et al.
Published: (2025-05-01)

Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy
by: Liuqing Yang, et al.
Published: (2024-10-01)

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Targeting Stat3 with conditional knockout or PROTAC technology alleviates renal injury by Limiting pyroptosisResearch in context
by: Ming-lu Ji, et al.
Published: (2025-06-01)

Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies
by: Daoyuan Huang, et al.
Published: (2025-02-01)

Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity
by: Yuqing Li, et al.
Published: (2025-06-01)

MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell
by: Zheng Yuan, et al.
Published: (2025-03-01)

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
by: Chao Wang, et al.
Published: (2022-12-01)

Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives
by: Daoyuan Huang, et al.
Published: (2025-04-01)

Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation
by: Xiuyun Li, et al.
Published: (2025-08-01)

Innovative PDK1‐Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer
by: Aohua Deng, et al.
Published: (2025-08-01)

Identification and removal of a cryptic impurity in pomalidomide-PEG based PROTAC
by: Bingnan Wang, et al.
Published: (2025-02-01)

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
by: André T. S. Vicente, et al.
Published: (2025-07-01)

FDA-approved kinase inhibitors in PROTAC design, development and synthesis
by: Kacper Kossakowski, et al.
Published: (2025-12-01)

The Peptide PROTAC Modality: A New Strategy for Drug Discovery
by: Youmin Zhu, et al.
Published: (2025-04-01)

TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease
by: Ana Luísa Rodriguez Gini, et al.
Published: (2025-06-01)

PROTAC-induced protein structural dynamics in targeted protein degradation
by: Kingsley Y Wu, et al.
Published: (2025-02-01)

Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
by: Sol Jeong, et al.
Published: (2025-05-01)

Oligonucleotide-based PROTACs to Degrade RNA- and DNA-Binding Proteins
by: Céline N. Weller, et al.
Published: (2025-03-01)

Chemical knockdown of Keap1 and homoPROTAC-ing allergic rhinitis
by: Jianyu Yan, et al.
Published: (2025-08-01)

Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
by: Xinchen Lu, et al.
Published: (2025-01-01)